1461051528-efa39a96-23d2-4358-b16d-0cb8f33f5bf7

1. A nitride semiconductor laser device comprising:
a nitride semiconductor laser element having a resonator end surface; and
a stem having said nitride semiconductor laser element, wherein
said nitride semiconductor laser element is enclosed within a cap that is joined to said stem, and
an atmosphere hermetically sealed within said cap the atmosphere having a dew point of at most \u221230\xb0 C. and an oxygen concentration of at most 100 ppm, wherein
said atmosphere comprises at least one selected from a group consisting of helium, argon, and nitrogen, and said atmosphere has a pressure higher than 100 kPa,
wherein the nitride semiconductor laser element is capable of emitting light with a wavelength of at most 420 nm.
2. The nitride semiconductor laser device according to claim 1, wherein
said atmosphere includes helium.
3. The nitride semiconductor laser device according to claim 1, wherein
said atmosphere includes nitrogen.
4. The nitride semiconductor laser device according to claim 2, wherein
said atmosphere has a pressure higher than 100 kPa.
5. The nitride semiconductor laser device according to claim 3, wherein
said atmosphere has a pressure higher than 100 kPa.
6. The nitride semiconductor laser device according to claim 1, wherein
said cap has a window and said window has a thickness of at least 0.5 mm and at most 1.0 mm.
7. The nitride semiconductor laser device according to claim 1, wherein
said cap is joined to said stem with a metal interposed therebetween.
8. The nitride semiconductor laser device according to claim 1, wherein
a heat sink having said nitride semiconductor laser element is provided within said cap.
9. The nitride semiconductor laser device according to claim 1, wherein
a light detecting element for detecting a laser beam from said nitride semiconductor laser element is provided within said cap.
10. The nitride semiconductor laser device according to claim 1, wherein the atmosphere comprises at least one selected from a group consisting of helium, argon, and nitrogen, and said atmosphere has a pressure higher than 100 kPa.
11. The nitride semiconductor laser device according to claim 1, further including a window in said cap for allowing a laser beam emitted from said nitride semiconductor laser element, wherein
said window is larger than a hole of said cap, and
said window is mounted from the inside of said cap so as to cover said hole.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A pharmaceutical suspension for use in a pump-driven pharmaceutical dosage form comprising a pharmaceutically active agent and a polyoxaester.
2. The suspension of claim 1 which is substantially free of solvents.
3. The suspension of claim 1, wherein the polyoxaester comprises reaction products of at least one diacid and at least one diol.
4. The suspension of claim 2, wherein the diacid is a polyglycolic diacid, a 3,6-trioxaundecanedioic diacid, a 3,6,9-trioxaundecanedioic diacid, or combinations thereof.
5. The suspension of claim 2, wherein the diol is an ethyleneglycol, a propanediol, a butanediol, a pentanediol, cyclopentanediol, a hexanediol, a cyclohexanediol, an octanediol, a decanediol, a dodecanediol, cyclohexanedimethanol, polyethyleneglycol, polypropyleneglycol, or combinations thereof.
6. The suspension of claim 1, wherein the polyoxaester comprises condensation products of a mixture comprising a polyglycolic diacid and an ethyleneglycol.
7. The suspension of claim 6 wherein the mixture further comprises a 3,6,9-trioxaundecanedioic diacid.
8. The suspension of claim 6 wherein a molecular weight of the polyoxaester is from approximately 1,000 to approximately 100,000.
9. The suspension of claim 1, wherein the polyoxaester comprises condensation products of a mixture comprising a 3,6,9-trioxaundecanedioic diacid and an ethyleneglycol.
10. The suspension of claim 9, wherein a molecular weight of the polyoxaester is from approximately 1,000 to approximately 100,000.
11. The suspension of claim 1 wherein the pharmaceutically active agent comprises a protein, peptide, small molecule, or combinations thereof.
12. The suspension of claim 1 wherein the pharmaceutically active agent comprises lysozyme, interferon, erythropoietin, granulocyte macrophage colony stimulating factor (GM-CSF), human growth hormone releasing hormone (huGHRH), insulin, desmopressin, infliximab, an antibody, an agent conjugated to a targeting ligand, bone morphogenic proteins, Nesiritide, alpha-interferon, beta-interferon, omega-interferon, adrenocorticotropic hormone, angiotensin I, angiotensin II, atrial natriuretic peptide, bombesin, bradykinin, calcitonin, cerebellin, dynorphin N, alpha endorphin, beta endorphin, endothelin, enkephalin, epidermal growth factor, fertirelin, follicular gonadotropin releasing peptide, galanin, glucagon, glucagon-like peptide-1 (GLP-1), gonadorelin, gonadotropin, goserelin, growth hormone releasing peptide, histrelin, human growth hormone, insulin, leuprolide, LHRH, motilin, nafarerlin, neurotensin, oxytocin, relaxin, somatostatin, substance P, tumor necrosis factor, triptorelin, vasopressin, nerve growth factor, blood clotting factors, ribozymes, antisense oligonucleotide, or combinations thereof.
13. The suspension of claim 1 wherein the pharmaceutically active agent comprises risperidone, paliperidone, ocaperidone, or combinations thereof.
14. A dosage form comprising:
a first wall that maintains its physical and chemical integrity during the life of the dosage form and is substantially impermeable to a pharmaceutical suspension;
a second wall that is partially permeable to an exterior fluid;
a compartment defined by the first wall and the second wall;
a pharmaceutical suspension that is positioned within the compartment and comprises a pharmaceutically active agent and a polyoxaester;
a pump in communication with the first wall, the second wall, and the compartment; and
an exit port in communication with the compartment.
15. The dosage form of claim 14 wherein the pump comprises an osmotic pump.
16. The dosage form of claim 14 wherein upon contact with an aqueous medium, the pharmaceutical suspension is flowable through the exit port under a force exerted by the pump under normal operating conditions.
17. The dosage form of claim 14 wherein the pharmaceutical suspension is substantially homogeneous for at least 3 months at 37\xb0 C.
18. A method comprising administering the dosage form of claim 14 to a mammal.
19. A method of making the dosage form of claim 14.
20. A kit comprising a dosage form of claim 14 and instructions for administering the dosage form.